Zydus Lifesciences has informed that it enclosed a copy of press release dated November 8, 2022, titled ‘Zydus receives final approval from the USFDA for Bisoprolol Fumarate and Hydrochlorothiazide Tablets’.
The above information is a part of company’s filings submitted to BSE.